Venetoclax: a new weapon to treat high-risk CLL
- PMID: 27178241
- DOI: 10.1016/S1470-2045(16)30100-0
Venetoclax: a new weapon to treat high-risk CLL
Comment on
-
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10. Lancet Oncol. 2016. PMID: 27178240 Clinical Trial.
Similar articles
-
Is venetoclax a new wonder drug in CLL?Br J Haematol. 2019 May;185(4):643-646. doi: 10.1111/bjh.15836. Epub 2019 Mar 11. Br J Haematol. 2019. PMID: 30859555 No abstract available.
-
Venetoclax for the treatment of chronic lymphocytic leukemia.Expert Opin Investig Drugs. 2017 Nov;26(11):1307-1316. doi: 10.1080/13543784.2017.1386173. Epub 2017 Oct 9. Expert Opin Investig Drugs. 2017. PMID: 28972395 Review.
-
Venetoclax Yields Strong Responses in CLL.Cancer Discov. 2016 Feb;6(2):113-4. doi: 10.1158/2159-8290.CD-NB2015-180. Epub 2015 Dec 23. Cancer Discov. 2016. PMID: 26701089
-
Venetoclax-rituximab holds substantial promise in CLL.Nat Rev Clin Oncol. 2018 Jun;15(6):344-345. doi: 10.1038/s41571-018-0017-z. Nat Rev Clin Oncol. 2018. PMID: 29651129 No abstract available.
-
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954. Drugs Today (Barc). 2016. PMID: 27252989 Review.
Cited by
-
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications.Leukemia. 2020 Feb;34(2):462-477. doi: 10.1038/s41375-019-0571-0. Epub 2019 Aug 29. Leukemia. 2020. PMID: 31467429
-
Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia.Nat Commun. 2017 Mar 17;8:14756. doi: 10.1038/ncomms14756. Nat Commun. 2017. PMID: 28303898 Free PMC article.
-
Targeting intrinsic cell death pathways to control fungal pathogens.Biochem Pharmacol. 2019 Apr;162:71-78. doi: 10.1016/j.bcp.2019.01.012. Epub 2019 Jan 17. Biochem Pharmacol. 2019. PMID: 30660496 Free PMC article. Review.
-
MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma.Cell Stress. 2022 Jan 17;6(2):21-29. doi: 10.15698/cst2022.02.264. eCollection 2022 Feb. Cell Stress. 2022. PMID: 35174317 Free PMC article.
-
Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.Cancers (Basel). 2019 Nov 21;11(12):1834. doi: 10.3390/cancers11121834. Cancers (Basel). 2019. PMID: 31766355 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources